TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02159027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
Study: NCT05213988
Drug: Fibrates
Normalized name: Fibrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg/day
Study: NCT03472508
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study: NCT03472508
Drug: Enalapril Maleate and Folic Acid Tablets (Yiye)
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study: NCT04601909
Drug: FX-322
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: active comparator
Study: NCT01440920
Drug: OCV-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously administered once a week, 4 times at the dose of 0.3 mg
Study: NCT01440920
Drug: OCV-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously administered once a week, 4 times at the dose of 1 mg
Study: NCT01440920
Drug: OCV-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously administered once a week, 4 times at the dose of 3 mg
Study: NCT01379209
Drug: RGI-2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single administration of RGI-2001 on Day 0 post AHSCT.
Study: NCT01379209
Drug: Calcineurin Inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Study: NCT01379209
Drug: Conditioning Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Study: NCT01379209
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01379209
Drug: Mofetil Mycophenolate
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03850587
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparator medication
Study: NCT03850587
Drug: Tramadol 37.5Mg+ Celecoxib 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental medication
Study: NCT03850587
Drug: Tramadol 75mg+ Celecoxib 200mg
Normalized name: celecoxib / tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental medication
Study: NCT03850587
Drug: Tramadol 150mg+ Celecoxib 200mg
Normalized name: celecoxib / tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental medication
Study: NCT00517062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo self-injected once a day subcutaneously at bedtime.
Study: NCT01739348
Drug: Placebo (Part I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single placebo tablet matching verubecestat treatment once daily, taken orally
Study: NCT00823108
Drug: GIK
Normalized name: Surgikos Tip Cleaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hour infusion of GIK solution
Study: NCT01740726
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
Study: NCT01769755
Drug: Vehicle Controlled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Study: NCT01825031
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg once daily for 5 days
Study: NCT01670266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01974609
Drug: Narcotic
Normalized name: narcotic antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone 5mg + acetaminophen 325 mg
Study: NCT01974609
Drug: non-narcotic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 600mg + acetaminophen 325 mg
Study: NCT01541293
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
Study: NCT00569530
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
Study: NCT02788864
Drug: Arterakine (DHA/piperaquine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
Study: NCT02788864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
Study: NCT01680172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of liquid placebo solution taken by mouth
Study: NCT03606824
Drug: Pitavastatin and levothyroxine
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
Study: NCT01273064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo).
Study: NCT03969888
Drug: Placebo ABBV-3067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet taken orally.
Study: NCT03969888
Drug: Placebo ABBV-2222
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule taken orally.
Study: NCT00143507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00083278
Drug: MDX-010
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00177671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02852083
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice daily p.o.
Study: NCT03947034
Drug: Drugs inducing hyperammonemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs susceptible to induce metabolic toxicities such as hyperammonemia
Study: NCT04002700
Drug: Typical Antipsychotics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
Study: NCT04002700
Drug: Atypical Antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
Study: NCT00780039
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study: NCT01178931
Drug: Crinone 8% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal-1x90mg
Study: NCT00933348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
Study: NCT01239680
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1 liter once over 6 hours
Study: NCT01239680
Drug: Placebo (for Glutamine)
Normalized name: glutamine Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Intravenously in 1 liter Lactated Ringer's
Study: NCT03617432
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT03617432
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT00855582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
Study: NCT01531179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 months
Study: NCT04208932
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitors
Study: NCT01013753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
Study: NCT01599962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration
Study: NCT04163263
Drug: BOS-356
Normalized name: BOS TAURUS EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel
Study: NCT04163263
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel
Study: NCT02260986
Drug: Placebo (for Dupilumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Study: NCT00853385
Drug: CP 690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
Study: NCT00853385
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
Study: NCT03383679
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment with capecitabine
Study: NCT00191919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01001104
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
Study: NCT01001104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection, QW for 12 weeks.
Study: NCT01381510
Drug: 5-alpha Reductase Inhibitor (5ARI)
Normalized name: 5.alpha.-hydroxy laxogenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 5ARI: Either dutasteride or finisteride
Study: NCT02397837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo match study drug
Study: NCT01055912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
Study: NCT01590615
Drug: Anti-HBV nucleoside/nucleotide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
Study: NCT03852576
Drug: KSP/QRH dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSP-QRH-E3-IRDye800 (Peptide 919288G)
Study: NCT03695094
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
Study: NCT02323334
Drug: LY3202626
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT02323334
Drug: Placebo (Part A, B, C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT02786667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months treatment with Placebo up to 8 mg per day with a titration period for one month
Study: NCT01834261
Drug: Syntocinon Nasal Spray, 40IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Study: NCT01834261
Drug: Syntocinon Placebo Formulation, 40IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Study: NCT03745781
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT04038125
Drug: Ozurdex Drug Implant Product
Normalized name: Ozurdex Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Ozurdex injection
Study: NCT00005585
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005585
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
Study: NCT00005585
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
Study: NCT00005585
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
Study: NCT03228914
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
Study: NCT04504760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo will be administered orally.
Study: NCT04504760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of placebo will be administered orally.
Study: NCT01666600
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
Study: NCT02580344
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
Study: NCT01158404
Drug: LY900009 - Dose Confirmation Phase (Part B)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met.
Study: NCT01692756
Drug: Kenalog or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01692756
Drug: Kenalog then Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01692756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00650624
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
Study: NCT00650624
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
Study: NCT01573377
Drug: Ethinylestradiol and Cyproterone Acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
Study: NCT00650624
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
Study: NCT00650624
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet by mouth once daily in the morning for 6 weeks
Study: NCT00528385
Drug: Spironolactone (Spironol) 25 mg
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
Study: NCT04556851
Drug: HSK7653 10 mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Study: NCT04556851
Drug: HSK7653 25 mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Study: NCT04556851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Study: NCT03986268
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
Study: NCT00899847
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
Study: NCT00899847
Drug: Solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
Study: NCT00899847
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
Study: NCT00899847
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
Study: NCT04626778
Drug: Peroxyl Mouthwash
Normalized name: Peroxyl Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash
Study: NCT04626778
Drug: Placebo Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash
Study: NCT03073057
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose